WOBURN, Mass.--(BUSINESS WIRE)--ArQule, Inc. (NASDAQ: ARQL - News) today announced the initiation of two Phase 2 trials with ARQ 197, an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase, in patients with MiT (Microphthalmia Transcription Factor) tumors and pancreatic cancer.
